The narrative around brain-computer interfaces has shifted. Clinical trials are no longer the constraint—they're accelerating. Paradromics completed the first wireless BCI implant in an ALS patient [S3], while Casey Harrell, paralyzed by ALS, has now operated a UC Davis brain implant for nearly three years, regaining speech, web access, and employment [S2]. These are not marginal proof-of-concept moments; they are becoming routine milestones.
Yet the success stories mask a harder question that investors have largely overlooked: can these devices sustain performance and user commitment over years, not months? Harrell's three-year operational history is exceptional precisely because it is rare. Most clinical BCI deployments remain short-lived demonstrations, not durable systems. The difference matters enormously for valuations built on deployed-user economics.
A second tension lies in the device-intervention trade-off. Adaptive deep brain stimulation for Parkinson's patients shows that closed-loop, responsive systems outperform static implants [S5]. Yet most communication-focused BCIs operate on open-ended neural interfaces—they record brain signals but don't actively adapt to degradation or fatigue. As users age or implants accumulate scar tissue, fidelity degrades. No vendor has yet published transparent degradation curves or refreshing protocols [S1].
The third issue is less visible but more urgent: we're confabulating user success. Harrell's narrative—the climate activist regaining agency—is compelling and real [S4]. But it obscures a triage problem. BCIs work best for highly motivated, cognitively intact patients with intact motor cortex. The broader ALS population includes severe cognitive decline and widespread neurodegeneration. The companies winning early trials are self-selecting for patients most likely to succeed, not most in need.
For investors, this means the bottleneck has migrated. It's no longer about surgical technique or neural recording quality. It's about: (1) demonstrating multi-year reliability without invasive re-intervention; (2) scaling to patients outside the ideal-case phenotype; and (3) building economically viable service models around device maintenance and signal drift. Companies publishing three-year safety and performance curves, and articulating refresh strategies, will command premium valuations. Those still anchored on clinical novelty will face a harder valuation reset.
